AUROC

New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients

Retrieved on: 
Tuesday, April 9, 2024
Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Clinical Trials, Science, Biotechnology, Health, Cancer, AUROC, Disease, Progression-free survival, Patient, Lung, Biomarker, RNA, EAP, Doctor of Philosophy, Biology, AACR, Receiver, Neoplasm, Drug development, FDA, Annual general meeting, Pharmaceutical industry

Genialis , the RNA-biomarker company, today presented a poster on a new AI/ML classifier, Genialis™ krasID, that accurately predicts clinical benefit in a real-world cohort of patients who received sotorasib, a KRAS inhibitor currently approved for KRAS G12C non-small cell lung cancers.

Key Points: 
  • Genialis , the RNA-biomarker company, today presented a poster on a new AI/ML classifier, Genialis™ krasID, that accurately predicts clinical benefit in a real-world cohort of patients who received sotorasib, a KRAS inhibitor currently approved for KRAS G12C non-small cell lung cancers.
  • Genialis krasID analyzes foundational aspects of KRAS biology using RNA-sequencing and a machine learning algorithm comprising numerous biologic signatures.
  • Taken together, these early results demonstrate that the Genialis krasID classifier can predict response and stratify durable benefit in experimental and clinical settings.
  • Last week, Genialis announced the addition of two new partners as it assembles the world’s most ethnographically diverse cancer data sets .

New Studies Demonstrate that Bot Image's Prostate Cancer AI Software Outperforms the Field

Retrieved on: 
Tuesday, January 30, 2024
MRI, Prostate cancer, Artificial intelligence, Multimedia, Men's Health, AI, Prostate, AUROC, Software, Artificiality, FDA, Clinical trial, Diagnosis, Medical imaging

and BELGRADE, Maine, Jan. 30, 2024 /PRNewswire/ -- Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company ( www.botimageai.com ), raised the performance bar with its FDA-cleared AI software ProstatID™.

Key Points: 
  • and BELGRADE, Maine, Jan. 30, 2024 /PRNewswire/ -- Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company ( www.botimageai.com ), raised the performance bar with its FDA-cleared AI software ProstatID™.
  • The unique trifecta clearance of this software used for prostate cancer detection, diagnosis and screening using non-invasive/non-contrast "short-form" of MRI sequences known as bi-parametric MRI (bpMRI) has demonstrated standalone performance of 93.6% AUROC (area under the sensitivity – specificity curve).
  • This is in stark contrast to results reported in recent articles reporting other Prostate AI products.
  • "Furthermore, if results are not reported in terms of the standalone performance of such software, then it's like comparing apples to oranges.

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology  

Retrieved on: 
Tuesday, September 26, 2023
Partnership, Nature Medicine, NASH, Regulation of tobacco by the U.S. Food and Drug Administration, Hepatology, Liver disease, AUROC, Biomarker, Fibrosis, Patient, Virginia Commonwealth University, Fatty liver disease, ALT, Diagnosis, Government, Phenotype, Pharmaceutical industry, Medical imaging, Euronext

The study aims to confirm the diagnostic performances of existing biomarker panels and determine their advantage over commonly used laboratory tests (ALT and FIB-4).

Key Points: 
  • The study aims to confirm the diagnostic performances of existing biomarker panels and determine their advantage over commonly used laboratory tests (ALT and FIB-4).
  • The findings, published in the scientific journal Nature Medicine, concluded that NIS4® achieved an AUROC6 of 0.815 for its intended use of diagnosing at-risk NASH, demonstrating significant superiority over common clinical-laboratory tools.
  • It also confirmed that NIS4® was the only panel efficient for the diagnosis of the composite phenotype of at-risk NASH.
  • NIS4®’s utility as an effective technology to diagnose at-risk NASH is clearly demonstrated in these findings and we look forward to evaluating NIS4®’s more advanced version, NIS2+™, in the near future.”

VUNO's First AI-based Prospective Study Results Published in Critical Care

Retrieved on: 
Monday, September 18, 2023
Blood pressure, Real, Dong-a University Hospital, Cardiac arrest, Cohort (statistics), Bed, Respiratory rate, National Early Music Association, MFDS, MEWS, Research, Multimedia, AUROC, RWD, Real World, Thermoregulation, Korean Ministry of Culture, Seoul National University Hospital, Vital signs, Patient, Patient safety, UIT, NEWS, Trial of the century, Heart rate, Medical device, Pharmaceutical industry, Nursing, Critical care, Food

VUNO announced that the multicenter clinical study paper, which confirms the clinical validity of VUNO Med®-DeepCARS™ through its initial prospective research, has been published in "Critical Care," a leading international journal in intensive care medicine.

Key Points: 
  • VUNO announced that the multicenter clinical study paper, which confirms the clinical validity of VUNO Med®-DeepCARS™ through its initial prospective research, has been published in "Critical Care," a leading international journal in intensive care medicine.
  • In the study published in Critical Care, the VUNO research team conducted a multicenter study using patient data from general wards at four tertiary medical institutions: Seoul National University Hospital, Bundang Seoul National University Hospital, Inha University Hospital, and Dong-A University Hospital, each with varying sizes, locations, and medical environments.
  • The study found that the predictive performance of VUNO Med®-DeepCARS™ had an AUROC score of 0.869, outperforming traditional methods (NEWS 0.767, MEWS 0.756).
  • In this study, VUNO Med®-DeepCARS™ displayed exceptional predictive abilities and adaptability in identifying high-risk patients, even in its first prospective research.

The FNIH Announces Study Results Published in Nature Medicine Showing That Liver Disease Can Be Diagnosed Using Noninvasive Blood Tests

Retrieved on: 
Thursday, September 7, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Knowledge, FNIH, Partnership, Drug development, Therapy, NASH, Liver disease, Research fellow, AUROC, Non-alcoholic fatty liver disease, Biomarker, Doctor of Philosophy, Bangladesh Technical Education Board, DSM-IV codes, Patient engagement in Canada, Liver cancer, Foundation for the National Institutes of Health, Kidney, Patient, Risk, Blood, Liver, Fatty liver disease, Mortality, United, Digestive, FDA, MPH, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cirrhosis, Food, Safety, Biopsy, Medical imaging, Nature Medicine, MD

The research is part of the Biomarkers Consortium’s Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) project, a public-private partnership bringing together the FDA, academic researchers, and industry partners to rigorously evaluate blood and imaging tests to measure the presence of liver disease.

Key Points: 
  • The research is part of the Biomarkers Consortium’s Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) project, a public-private partnership bringing together the FDA, academic researchers, and industry partners to rigorously evaluate blood and imaging tests to measure the presence of liver disease.
  • Although several companies have developed such tests, none have met the burden of proof needed for FDA regulatory approval.
  • This lack of approval limits the use of these tests for diagnosing NASH and recruiting patients into studies to develop therapies.
  • For more information, visit Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) | FNIH .

DermaSensor Study Results For Skin Cancer Detection Device Performance Across Skin Tones Of Over 1,000 Patients

Retrieved on: 
Thursday, August 10, 2023
Oncology, Medical Devices, Health, Health Technology, Other Health, General Health, DERM, FST, Yale School of Medicine, PCP, Skin cancer, Receiver, Coronavirus Scientific Advisory Board, Yale school, AUROC, ESS, Gold, Patient, Otorhinolaryngology, Skin, Medical imaging, Dermatology

Forty-eight skin cancers were detected in subjects with Fitzpatrick skin type IV-VI.

Key Points: 
  • Forty-eight skin cancers were detected in subjects with Fitzpatrick skin type IV-VI.
  • Importantly, there was minimal variation in device sensitivity, specificity, and Area under the Receiver Operating Characteristic Curve (AUROC) when comparing patients in the two FST subgroups to each other and to overall study results.
  • "Our mission at DermaSensor has always been to provide access to tools to aid in skin cancer evaluations”, said Cody Simmons, CEO of DermaSensor.
  • “The results from the DERM-SUCCESS study suggest that our ESS technology performs comparably regardless of skin type, which could improve providers’ ability to assess lesions on all patients and thus increase equitable access to effective skin cancer exams.”

Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination - Published in Radiology

Retrieved on: 
Monday, July 3, 2023
Radiology, Cancer, Lung cancer, AUROC, Radiological Society of North America, Seoul National University Hospital, Patient, Reading, AI, RSNA, Medical imaging, Medical device

SEOUL, South Korea, July 3, 2023 /PRNewswire/ -- Findings from a recent study demonstrate that medical AI solutions with only high diagnostic accuracy can significantly improve the reading performance of radiologists.

Key Points: 
  • Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostics solutions, today announced the publication of a study exploring the impact of medical AI solutions' accuracy on radiologists' diagnostic determination.
  • A total of 120 retrospectively collected chest radiographs were assessed, with 60 obtained from patients with lung cancer and the remaining 60 showing no abnormalities.
  • In the subsequent session, each group reinterpreted the images with the aid of either a high-accuracy or low-accuracy AI model.
  • Instead, the accuracy of the AI model and the radiologists' initial diagnostic accuracy emerged as the primary determinant shaping the final diagnostic determination.

New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery

Retrieved on: 
Thursday, March 9, 2023
Medical Devices, Health, Surgery, Biometrics, Health Technology, Cardiology, Transesophageal echocardiogram, Peking University, Neurosurgery, Doppler effect, SVV, Patient, Pediatrics International, PI, MASI, PPV, PVI, Cardiac output, CI, Fluid, Heart rate, AUROC, Multimedia, FDA, Edwards Lifesciences, Stroke, Anesthesia, Medical imaging, Medical device, Masimo

The researchers enrolled 60 patients, aged 1-3, who were undergoing major neurosurgery with mechanical ventilation set at a fixed tidal volume of 8 ml/kg.

Key Points: 
  • The researchers enrolled 60 patients, aged 1-3, who were undergoing major neurosurgery with mechanical ventilation set at a fixed tidal volume of 8 ml/kg.
  • The researchers concluded, “Volume-based PVI and ∆Vpeak showed acceptable reliabilities to predict fluid responsiveness, defined by a CI increase, after anesthesia induction in mechanically ventilated young children undergoing major neurosurgery.
  • Accuracy of PVi in predicting fluid responsiveness is variable and influenced by numerous patient, procedure and device related factors.
  • Fluid management decisions should be based on a complete assessment of the patient’s condition and should not be based solely on PVi.

Lunit AI Can Help Tuberculosis Screening in Prisons, as Published in The Lancet Regional Health - Americas

Retrieved on: 
Thursday, December 15, 2022
INSIGHT, TPP, Mato, Algorithm, General medical journal, Prison, Tuberculosis, AI, Federal University of Mato Grosso do Sul, World Health Organization, Sputum, Multimedia, WHO, TB, Lancet, National university, AUROC, Radiology, CAD, Male, Pharmaceutical industry, Medical device, Medical imaging

The AI solution can detect 10 of the most common chest abnormalities, including tuberculosis, with 97-99% accuracy.

Key Points: 
  • The AI solution can detect 10 of the most common chest abnormalities, including tuberculosis, with 97-99% accuracy.
  • Researchers performed prospective TB screening in three male prisons in Brazil from October 2017 to December 2019.
  • The Lancet is an international peer-reviewed general medical journal and the world's highest-impact academic journal (impact factor: 202.7).
  • [2]WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease, 2021
    View original content to download multimedia: https://www.prnewswire.com/news-releases/lunit-ai-can-help-tuberculosis-...

Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis

Retrieved on: 
Friday, November 12, 2021
Mental Health, Health, Medical Devices, Other Health, General Health, Clinical Trials, Biotechnology, Health, Amnesia, Efficiency, CSF, CL, Biomarker, Center for Epidemiologic Studies Depression Scale, APS, Diagnosis, PET, AD, M.B.A, Clinical trial, CEO, Disease, Government budget balance, Research, AUROC, Amyloid, George Washington University School of Medicine & Health Sciences, Mass spectrometry, Brown University, Annual general meeting, Data, Americas Society, Neurodegeneration, Physician, Washington University School of Medicine, Pathology, GSA, Time, Gerontological Society of America, Patient, Risk, Ageing, Brain, Medical imaging, Pharmaceutical industry, Medical device, Medicine

The PrecivityAD test is a breakthrough blood test intended for use in patients with cognitive impairment.

Key Points: 
  • The PrecivityAD test is a breakthrough blood test intended for use in patients with cognitive impairment.
  • The test helps physicians determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimers disease (AD).
  • The AUROC for the PrecivityAD blood test with CSF biomarker status was 0.92.
  • Prediction of Brain Amyloid Pathology Using Plasma A42/40 Ratio Measured Using PrecivityAD Test in the MissionAD Study Samples also delivered important findings.